Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Allopurinol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH known ✓ | P47989 | 2/20 | 0.61 |
| ▸ | RET | P07949 | 1/20 | 0.61 |
| ▸ | PI4KA | P42356 | 1/20 | 0.61 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | AKT2 | P31751 | 2/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Allopurinol SCHEMBL29693720 | 1.00 | XDH (0.61) | XDHRETPI4KALRRK2PI4K2B | |
| Allopurinol SCHEMBL4627 | 1.00 | XDH (0.61) | XDHRETPI4KALRRK2PI4K2B | |
| Allopurinol SCHEMBL21362860 | 0.98 | XDH (0.59) | XDHRETPI4KALRRK2PI4K2B | |
| Allopurinol SCHEMBL6142912 | 0.98 | XDH (0.59) | XDHRETPI4KALRRK2PI4K2B | |
| Allopurinol SCHEMBL137084 | 0.98 | XDH (0.59) | XDHRETPI4KALRRK2PI4K2B | |
| Allopurinol SCHEMBL7202468 | 0.98 | XDH (0.59) | XDHRETPI4KALRRK2PI4K2B | |
| Allopurinol SCHEMBL2563568 | 0.98 | XDH (0.59) | XDHRETPI4KALRRK2PI4K2B | |
| Allopurinol SCHEMBL9245969 | 0.91 | CYP1A2 (0.54) | XDHRETPI4KALRRK2PI4K2B | |
| Allopurinol SCHEMBL9421599 | 0.89 | PDPK1 (0.50) | XDHRETPI4KALRRK2PI4K2B | |
| Allopurinol SCHEMBL9421602 | 0.89 | XDH (0.50) | XDHRETPI4KALRRK2PI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007149103-A2 | VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE | KAISER DANIEL E (US) | 2007-12-27 | — | — | WO | claimed |
| EP-3534905-A1 | SMALL MOLECULE DUAL INHIBITORS OF EGFR/PI3K AND USES THEREOF | The Regents of The University of Michigan (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-3380522-A1 | ANTIBODY MOLECULES TO APRIL AND USES THEREOF | Visterra, Inc. (US) | 2018-10-03 | — | — | EP | disclosed |
| WO-2017091683-A1 | ANTIBODY MOLECULES TO APRIL AND USES THEREOF | Visterra, Inc. (US) | 2017-06-01 | — | — | WO | disclosed |
| EP-3137065-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | Pharnext (FR) | 2017-03-08 | — | — | EP | disclosed |
| EP-2970965-A2 | DNAI FOR THE MODULATION OF GENES | Pronai Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015165948-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | PHARNEXT (FR) | 2015-11-05 | — | — | WO | disclosed |
| WO-2014144942-A2 | DNAI FOR THE MODULATION OF GENES | PRONAI THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-1915377-A1 | PYRAZOLO PYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007013964-A1 | PYRAZOLO PYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2007-02-01 | — | — | WO | disclosed |